Factor Report

Data as of market close on 11/20/2020.

Validea's factor report analyzes any stock using the major investing factors, including value, quality, momentum, and low volatility.
View User Guide    Video Tutorial


View Guru Analysis
Latest Close: $35.18 Market Cap ($ mil): $665 Sector: Healthcare Industry: Biotechnology & Drugs 52 Week High: $49.00 52 Week Low: $11.26 Relative Strength: 85 Twelve Minus One Return: 79.6% Standard Deviation: 68.9%
PE Ratio: N/A Price/Sales: 55.3 Price/Book: 3.1 Price/Cash Flow: N/A EV/EBITDA: N/A Yield: N/A Shareholder Yield: -56.23% F Score: 2 G Score: 3
Return on Equity: -57.7% Return on Assets: -37.5% Return on Tangible Capital: -31.1% Return on Invested Capital: N/A WACC: N/A Debt/Equity: 0.00 LT EPS Growth: N/A LT Sales Growth: 218.4% Beta: 1.60
Albireo Pharma, Inc., formerly Biodel Inc., is a specialty biopharmaceutical company. It is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI), disorders where improper flow or absorption of bile causes serious medical conditions for which there is unmet need. The target indication for its lead product candidate, A4250, is progressive familial intrahepatic cholestasis (PFIC), which is a genetic disorder affecting children. A4250 is being evaluated in a Phase II clinical trial. Other products in the Company's pipeline include Elobixibat, A3384 and Bile Acid Modulators. Elobixibat is indicated for the treatment of chronic constipation and it has completed its Phase III clinical trials. A3384 is a formulation of cholestyramine that is designed to release cholestyramine directly in the colon. It has completed a Phase II clinical trial of a prior formulation of A3384 in bile acid malabsorption (BAM).

Factor Profile

ALBO's exposure to the major factors (100 is highest).

Comparable Stocks

Stocks with the closest factor profiles to ALBO.

(click ticker to access stock report and name to view guru analysis)

Ticker Ticker
Performance Disclaimer: Returns presented on Validea.com are model returns and do not represent actual trading. As a result, they do not incorporate any commissions or other trading costs or fees. Model portfolios with inception dates on or after 12/30/2005 include a combination of back tested and live model returns. The back-tested performance results shown are hypothetical and are not the result of real-time management of actual accounts. The back-testing of performance differs from actual account performance because the investment strategy may be adjusted at any time, for any reason and can continue to be changed until desired or better performance results are achieved. Back-tested returns are presented to provide general information regarding how the underlying strategy behind the portfolio performed in our historical testing. A back-tested strategy has the benefit of hindsight and the results do not reflect the impact that material economic or market factors may have had on advisor's decision-making if actual client assets were being managed using this approach.

Optimal portfolios presented on Validea.com represent the rebalancing period that has led to the best historical performance for each of our equity models. Each optimal portfolio was determined after the fact with performance information that was not available at portfolio inception. As a result, an investor could not have invested in the optimal portfolio since its inception. Optimal portfolios are presented to allow investors to quickly determine the portfolio size and rebalancing period that has performed best for each of our models in our historical testing.

Both the model portfolio and benchmark returns presented for all equity portfolios on Validea.com are not inclusive of dividends. Returns for our ETF portfolios and trend following system, and the benchmarks they are compared to, are inclusive of dividends. The S&P 500 is presented as a benchmark because it is the most widely followed benchmark of the overall US market and is most often used by investors for return comparison purposes. As with any investment strategy, there is potential for profit as well as the possibility of loss and investors may incur a loss despite a past history of gains. Past performance does not guarantee future results. Results will vary with economic and market conditions.